Life sciences companies in the U.S. raised roughly $404 million through ATMs in 2012, compared to $227 million in 2011, a 78 percent year-over-year increase.
In the fourth quarter of 2012, life sciences companies raised $128 million through ATMs, compared to $101 million in the third quarter, a 27 percent increase. This ATM activity included the following companies: StemCells Inc. (NASDAQ: STEM), Newark, Calif.; Sarepta Therapeutics Inc. (NASDAQ: SRPT), Cambridge, Mass.; Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), San Francisco, Calif.; Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), San Diego, Calif.
“The continued uptrend in ATM adoption and usage by life sciences companies is evident in these numbers,” says Todd Wyche, CEO of Brinson Patrick. “As we have predicted, an increasing number of life sciences companies continue to add ATMs to their financing toolkits to lower their cost of capital and avoid unnecessary dilution.”